NASDAQ · IONS
Ionis Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IONS: Nov 4, 2026
Ionis Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 9 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.22. The reported EPS for the same quarter last year was $-0.8.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.22 | $-0.98 | $-1.37 | 9 |
| Dec 2026 | $-1.08 | $-0.99 | $-1.23 | 8 |
| Mar 2027 | $-0.91 | $-0.75 | $-1.00 | 4 |
| Jun 2027 | $-0.72 | $-0.64 | $-0.78 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · The Motley Fool- Zacks · Oct 29, 9:00 AM EDTARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineIonis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 10:49 AM EDTNVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues MissNovartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
- RTTNews · Oct 24, 12:44 AM EDTRoche Reports Positive Phase III Data For Investigational IgAN Therapy Sefaxersen(RTTNews) – Roche (RHHBY) announced new late-breaking data from the ongoing Phase III IMAgINATION study showing that its investigational therapy sefaxersen delivered a statistically significant and clinically meaningful reduction in proteinuria in adults with primary IgA nephropa
- Fintel · Oct 23, 1:49 PM EDTIonis Pharmaceuticals, Inc. Partner Roche Announces Positive Phase 3 IMAgINATION Data for Sefaxersen in IgA NephropathyOn October 23, 2026, Ionis Pharmaceuticals, Inc. issued a press release reporting that its partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demons
- Fintel · Oct 22, 1:38 AM EDTIonis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% RoyaltiesIonis Pharmaceuticals, Inc. reported that its partner, GSK, announced that the U.S. Food and Drug Administration has approved HIBSAGO for the treatment of chronic hepatitis B virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor therapy in adu
- The Motley Fool · Oct 21, 5:04 AM EDTAlnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?Alnylam's stock has plunged more than 40% this year, but the company's financials look great.
- Fintel · Oct 16, 8:11 PM EDTUBS Upgrades Ionis Pharmaceuticals to Buy from NeutralFintel reports that on October 15, 2026, UBS upgraded their outlook for Ionis Pharmaceuticals (NASDAQGS:IONS) (LSE:0JDI) from Neutral to Buy.Prior to this rating action, the stock closed at $42.70 on October 14, 2026. Following the action, the next-session close was recorded at $
- RTTNews · Oct 16, 3:02 PM EDTFDA Drug Approvals In September 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment
- Barchart · Oct 16, 1:24 PM EDTStocks Settle Mixed as Broader Market Recovers from Chip Stock RoutThe S&P 500 Index ($SPX ) (SPY ) closed up by +0.33% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. December E-mini S&P futures (ESZ26 ) rose +0.28%, and December E-mini…
- RTTNews · Oct 16, 7:58 AM EDTCHMP Recommends Ioni's TRYNGOLZA Approval For Several Hypertriglyceridemia In EU(RTTNews) – Ionis Pharmaceuticals (IONS) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending an indication extension for TRYNGOLZA for the treatment of adults with severe hypertriglyceridemia (sHTG). The therapy would be used as an
- RTTNews · Oct 16, 7:36 AM EDTCHMP Backs Ionis TRYNGOLZA For Severe Hypertriglyceridemia In Europe(RTTNews) – On Friday, Ionis Pharmaceuticals (IONS) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of TRYNGOLZA (olezarsen) for adults with severe hypertriglyceridemia (sHTG).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Ionis Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.